IP Library Granted Patent US 10,683,324
Granted Patent B2
US 10,683,324 · App. 15/990,235 · Granted Jun 16, 2020

7-dehydrocholesterol derivatives and methods using same

Inventors: Rakesh K. Singh (Rochester, NY); Richard G. Moore (Rochester, NY)
Assignee: University of Rochester
C07J71/0042A61K31/401A61K31/415A61K31/565A61K31/575A61K31/58A61K45/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,683,324
App. No.
15/990,235
Granted
Jun 16, 2020
Kind
B2
Abstract

The present invention provides, in certain aspects, novel 7-dehydrocholesterol (7DHC) derivatives that are useful in treating or preventing cancer, as well as in treating or preventing uncontrolled angiogenesis, in a subject. In certain embodiments of the present invention, the subject is a human. In other aspects, the present invention provides a method of preparing compounds of the invention, or a salt or solvate thereof.

Claims (28)

1. A method of treating a cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of at least one compound of formula (I) or a salt or solvate thereof:

wherein in (I):

R 1 is CR 5 or N;

R 3 is selected from the group consisting of —O(CR 5 ) n R 6 , —OC(—O)(CR 5 ) n R 6 , —OC(═O)(CR 5 ) n OR 5 , and —OC(═O)C(R 5 )═C(R 5 ) 2 ;

R 2 is selected from the group consisting of O, S, C(R 4 ) 2 , and N(R 4 );

each occurrence of R 4 is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, OR 5 , and N(R 5 ) 2 ;

each occurrence of R 5 is independently selected from the group consisting of H, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, and substituted heteroarylalkyl;

R 6 is selected from the group consisting of F, Cl, Br, I, mesyl, tosyl, —OSi(R 5 ) 3 , —C(═O)OR 5 , and —C(═O)R 5 ;

the dotted line is a single or double bond; and,

n is an integer ranging from 1 to 10,

wherein said cancer comprises ovarian cancer, endometrial cancer, breast cancer, prostate cancer, lung cancer, renal cancer, liver cancer, neuroblastoma, melanoma, medulloblastoma, pancreatic cancer, leukemia or a combination thereof.

2. The method of claim 1 , wherein the compound of formula (I) is the compound of formula (Ia), or a salt or solvate thereof:

3. The method of claim 2 , wherein the compound of formula (I) is the compound of formula (Ib), or a salt or solvate thereof:

4. The method of claim 1 , wherein R 1 is N.

5. The method of claim 4 , wherein R 2 is N(R 4 ).

6. The method of claim 5 , wherein the compound of formula (I) is the compound of formula (Ic), or a salt or solvate thereof:

7. The method of claim 6 , wherein the compound of formula (I) is the compound of formula (Id), or a salt or solvate thereof:

8. The method of claim 1 , wherein the compound of formula (I) is selected from the group consisting of:

9. The method of claim 1 , wherein the subject is further administered at least one additional chemotherapeutic agent.

10. The method of claim 9 , wherein at least one agent is selected from the group consisting of alkylating agents; nitrosoureas; antimetabolites; antitumor antibiotics; plant alkyloids; taxanes; hormonal agents; anti-angiogenesis agents, bleomycin, hydroxyurea, L-asparaginase, and procarbazine.

11. The method of claim 9 , wherein the compound and the agent are separately administered to the subject.

12. The method of claim 9 , wherein the compound and the agent are coadministered to the subject.

13. The method of claim 1 , wherein the subject is a mammal.

14. The method of claim 13 , wherein the mammal is a human.

15. The method of claim 1 , wherein the compound is administered to the subject by at least one route selected from the group consisting of intravenous, oral, inhalational, rectal, vaginal, transdermal, intranasal, buccal, sublingual, parenteral, intrathecal, intragastrical, ophthalmic, pulmonary and topical routes.

16. The method of claim 1 , further comprising procuring the compound of formula (I) for the subject.

17. The method of claim 1 , wherein the compound of formula (I) is:

18. The method of claim 1 , wherein the subject is further administered radiation therapy.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: WOMEN & INFANTS HOSPITAL OF RHODE ISLAND
To: UNIVERSITY OF ROCHESTER
Reel/Frame 046456/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: SINGH, RAKESH K.; MOORE, RICHARD G.
To: WOMEN & INFANTS HOSPITAL OF RHODE ISLAND
Reel/Frame 046456/0934 →
Continuity (3)
Division 15302898
Provisional Application 61976148 · Apr 7, 2014
Related Publication 20180273580A1 · Sep 27, 2018